Overview

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Status:
Recruiting

Trial end date:
2026-07-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bevacizumab
Durvalumab